My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Septerna, Inc. - Common Stock (NQ:SEPN)

17.16 +0.41 (+2.45%)
Streaming Delayed Price Updated: 12:44 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Septerna, Inc. - Common Stock

Septerna to Participate in Upcoming Investor Conferences
From Septerna, Inc.
Via GlobeNewswire
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers 
From Septerna, Inc.
Via GlobeNewswire
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Septerna to Present at Jefferies Global Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
From Septerna, Inc.
Via GlobeNewswire
SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Septerna to Present at TD Cowen 45th Annual Health Care Conference
From Septerna, Inc.
Via GlobeNewswire
SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
From Septerna, Inc.
Via GlobeNewswire
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
From Septerna, Inc.
Via GlobeNewswire
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Septerna, Inc.
Via GlobeNewswire
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
From Septerna, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.